Bosutinib

Phase 1/2Active

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Chromosome Positive CML

Conditions

Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia

Trial Timeline

Jul 6, 2020 → Jul 1, 2028

NCT ID

NCT04258943

About Bosutinib

Bosutinib is a phase 1/2 stage product being developed by Pfizer for Philadelphia Chromosome Positive CML. The current trial status is active. This product is registered under clinical trial identifier NCT04258943. Target conditions include Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia.

What happened to similar drugs?

2 of 8 similar drugs in Philadelphia Chromosome Positive CML were approved

Approved (2) Terminated (1) Active (5)

✅NilotinibNovartisApproved

✅AsciminibNovartisApproved

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

🔄Asciminib + NilotinibNovartisPhase 3

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05363488	Pre-clinical	Completed	Oct 8, 2021	Oct 8, 2021	Myeloid Leukemia
NCT04258943	Phase 1/2	Active	Jul 6, 2020	Jul 1, 2028	Philadelphia Chromosome Positive CML
NCT03128411	Phase 2	Completed	May 15, 2017	Mar 4, 2021	Leukemia, Chronic Myelogenous
NCT02906696	Phase 2	Terminated	Oct 28, 2016	Aug 8, 2019	Blasts Under 15 Percent of Bone Marrow Nucleated Cells
NCT02921477	Phase 1	UNKNOWN	Sep 1, 2016	Dec 31, 2025	Mild Cognitive Impairment
NCT02546375	Pre-clinical	Completed	Jul 15, 2015	Jan 16, 2017	Chronic Myeloid Leukaemia
NCT02501330	Pre-clinical	Completed	Jul 1, 2015	Feb 28, 2024	Chronic Myelogenous Leukemia
NCT02228382	Approved	Terminated	Nov 7, 2014	Oct 13, 2020	Previously Treated PH + CML
NCT01903733	Pre-clinical	Completed	Aug 28, 2013	Jun 5, 2020	Chronic Myeloid Leukemia
NCT01331291	Phase 2	Completed	Apr 1, 2011	Dec 1, 2014	Glioblastoma
NCT00759837	Phase 1	Completed	Oct 1, 2008	May 1, 2009	Breast Cancer
NCT00725426	Phase 1	Completed	Jul 1, 2008	Aug 1, 2008	Healthy
NCT00261846	Phase 2	Completed	Jan 18, 2006	Aug 6, 2015	Chronic Myeloid Leukemia

Competing Products

20 competing products in Philadelphia Chromosome Positive CML

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	35
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	35
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	42
nilotinib	Novartis	Phase 2	35
Asciminib + Nilotinib	Novartis	Phase 3	44
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib	Novartis	Phase 1	36
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib + LDE225	Novartis	Phase 1	29
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib + Bosutinib	Pfizer	Phase 1	29